Adapted Evidence-Based Clinical Practice Guidelines for Diagnosis and Treatment of Epilepsies in Children: A Tertiary

Shimaa A M Anwar1, Elham E Elsakka1, Mona Khalil1

  • 1Paediatric Neurology Unit, Faculty of Medicine, Paediatrics Department, Alexandria University, Alexandria, Egypt.

Pediatric Neurology
|February 12, 2023
PubMed

Insights

This study updated clinical practice guidelines for diagnosing and treating childhood epilepsy, unifying care standards. The revised guidelines offer comprehensive, evidence-based recommendations for healthcare providers to improve patient outcomes.

Area of Science:

  • Pediatric Neurology
  • Clinical Practice Guidelines
  • Evidence-Based Medicine

Background:

  • Medical knowledge evolves, necessitating regular updates to clinical practice guidelines (CPGs) for optimal patient care.
  • Alexandria University Children Hospital (AUCH) sought to unify and standardize the diagnosis and treatment of childhood epilepsy by updating existing CPGs from 2014 and 2016.

Approach:

  • A Guideline Review Group (GRG) updated CPGs using a high-quality source from the Scottish Intercollegiate Guidelines Network (SIGN).
  • The GRG employed the Checklist for the Reporting of Updated Guidelines (CheckUp) and the RIGHT-Ad@pt Checklist for adapted CPGs.
  • Recommendations were reviewed and updated across 10 key categories, covering the full spectrum of epilepsy management in children.

Key Points:

  • The updated CPG integrates diagnosis, pharmacological and non-pharmacological treatments, pharmacoresistant epilepsy management, and care for special populations.
  • Key areas include medication management, patient and caregiver education, comorbidity management, and transitional care from pediatric to adult services.
  • The process highlighted the value of collaborative expert groups and standardized reporting tools for CPG updates.

Conclusions:

  • The finalized CPG provides AUCH healthcare providers with evidence-based guidance for diagnosing and managing childhood epilepsy.
  • This update standardizes care, aiming for improved outcomes in pediatric epilepsy management.
  • The study underscores the importance of collaborative efforts and validated tools in the CPG update process.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
240
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
512
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
498
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
104
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
460
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
238